- Home
- KNOP vs CHRS Comparison
KNOP vs CHRS Comparison
Compare KNOP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNOP
- CHRS
- Stock Information
- Founded
- KNOP 2013
- CHRS 2010
- Country
- KNOP United Kingdom
- CHRS United States
- Employees
- KNOP N/A
- CHRS N/A
- Industry
- KNOP Marine Transportation
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KNOP Consumer Discretionary
- CHRS Health Care
- Exchange
- KNOP Nasdaq
- CHRS Nasdaq
- Market Cap
- KNOP 254.2M
- CHRS 84.2M
- IPO Year
- KNOP 2013
- CHRS 2014
- Fundamental
- Price
- KNOP $6.69
- CHRS $0.80
- Analyst Decision
- KNOP
- CHRS Buy
- Analyst Count
- KNOP 0
- CHRS 3
- Target Price
- KNOP N/A
- CHRS $4.68
- AVG Volume (30 Days)
- KNOP 50.1K
- CHRS 1.3M
- Earning Date
- KNOP 09-02-2025
- CHRS 08-07-2025
- Dividend Yield
- KNOP 1.66%
- CHRS N/A
- EPS Growth
- KNOP N/A
- CHRS N/A
- EPS
- KNOP 0.19
- CHRS N/A
- Revenue
- KNOP $320,026,000.00
- CHRS $272,251,000.00
- Revenue This Year
- KNOP $6.77
- CHRS N/A
- Revenue Next Year
- KNOP $0.81
- CHRS $106.56
- P/E Ratio
- KNOP $33.20
- CHRS N/A
- Revenue Growth
- KNOP 8.76
- CHRS 19.87
- 52 Week Low
- KNOP $5.28
- CHRS $0.66
- 52 Week High
- KNOP $8.63
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- KNOP 55.53
- CHRS 51.58
- Support Level
- KNOP $6.29
- CHRS $0.72
- Resistance Level
- KNOP $6.75
- CHRS $0.77
- Average True Range (ATR)
- KNOP 0.23
- CHRS 0.04
- MACD
- KNOP -0.02
- CHRS 0.01
- Stochastic Oscillator
- KNOP 62.35
- CHRS 85.96
About KNOP KNOT Offshore Partners LP Common Units representing Limited Partner Interests
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.